BMO Capital Markets Raises Neurogene (NASDAQ:NGNE) Price Target to $26.00
Neurogene (NASDAQ:NGNE – Get Free Report) had its price objective boosted by investment analysts at BMO Capital Markets from $22.00 to $26.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 31.58% from the company’s […]
Neurogene (NASDAQ:NGNE – Get Free Report) had its price objective boosted by investment analysts at BMO Capital Markets from $22.00 to $26.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 31.58% from the company’s […]
